Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 42-50

  Xing, Mingzhao ^a   Alzahrani, Ali S ^a   Carson, Kathryn A ^b   Shong, Young Kee ^c   Kim, Tae Yong ^c   Viola, David ^d   Elisei, Rossella ^d   Bendlová, Bela ^j   Yip, Linwah ^k   Mian, Caterina ^e   Vianello, Federica ^f   Tuttle, R Michael ^l   Robenshtok, Eyal ^l   Fagin, James A ^l   Puxeddu, Efisio ^g   Fugazzola, Laura ^h   Czarniecka, Agnieszka ^m   Jarzab, Barbara ^m   O'Neill, Christine J ⁿ   Sywak, Mark S ⁿ   Lam, Alfred K ^o   Riesco Eizaguirre, Garcilaso ^p,q   Santisteban, Pilar ^q   Nakayama, Hirotaka ^r   Clifton Bligh, Roderick ⁿ   Tallini, Giovanni ⁱ   Holt, Elizabeth H ^s   Sýkorová, Vlasta ^j   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c University of Ulsan College of Medicine   (South Korea)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o GRIFFITH UNIVERSITY   (Australia)

^p HOSPITAL DE MÓSTOLES   (Spain)

^q INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^r KANAGAWA CANCER CENTER   (Japan)

^s YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAPILLARY THYROID CANCER; RECURRENCE RISK; RETROSPECTIVE STUDY; THYROID CANCER; CLINICAL TRIAL; FOLLOW UP; GENETICS; MIDDLE AGED; MISSENSE MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THYROID NEOPLASMS;

EID: 84920593838     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.8253     Document Type: Article

References (38)

1. Jemal A, Bray F, Center M.M., et al.: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Howlader N, Noone AM, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. http://seer.cancer.gov/csr/1975-2010/
3. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428, 1994
4. Tuttle RM, Ball DW, Byrd D, et al.: Thyroid carcinoma. J Natl Compr Canc Netw 8:1228-1274, 2010
5. Brown RL, de Souza JA, Cohen EE: Thyroid cancer: Burden of illness and management of disease. J Cancer 2:193-199, 2011
6. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262, 2005
7. Xing M: BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762, 2007
8. Kim TH, Park YJ, Lim J.A., et al.: The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta-analysis. Cancer 118:1764-1773, 2012
9. Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet 381:1058-1069, 2013
10. Xing M, Alzahrani AS, Carson K.A., et al.: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501, 2013
11. Puxeddu E, Moretti S, Elisei R., et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420, 2004
12. Fugazzola L, Mannavola D, Cirello V., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61:239-243, 2004
13. Xing M, Westra WH, Tufano R.P., et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379, 2005
14. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, et al.: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 13:257-269, 2006
15. Nakayama H, Yoshida A, Nakamura Y., et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas Anticancer Res 27:3645-3649, 2007
16. Elisei R, Ugolini C, Viola D., et al.: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949, 2008
17. Xing M, Clark D, Guan H., et al.: BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982, 2009
18. Yip L, Nikiforova MN, Carty S.E., et al.: Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215-1223, 2009
19. Ricarte-Filho JC, Ryder M, Chitale D.A., et al.: Mutational profile of advanced primary and meta-static radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893, 2009
20. Sykorova V, Dvorakova S, Ryska A., et al.: BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 33:318-324, 2010
21. Czarniecka A, Rusinek D, Stobiecka E., et al.: Occurrence of BRAF mutations in a Polish cohort of PTC patients: Preliminary results. Endokrynol Pol 61:462-466, 2010
22. O'Neill CJ, Bullock M, Chou A., et al.: BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148:1139-1145, 2010
23. Pelizzo MR, Boschin IM, Barollo S, et al.: BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor: A mono-institutional experience. Clin Chem Lab Med 49:325-329, 2011
24. Smith RA, Salajegheh A, Weinstein S., et al.: Correlation between BRAF mutation and the clinico-pathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 42:500-506, 2011
25. Kim TY, Kim WB, Rhee Y.S., et al.: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364-368, 2006
26. Pacini F, Schlumberger M, Dralle H., et al.: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803, 2006
27. Cooper DS, Doherty GM, Haugen B.R., et al.: American Thyroid Association (ATA) Guidelines Taskforce on thyroid nodules and differentiated thyroid cancer: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214, 2009
28. Hosmer DW, Lemeshow S: Confidence interval estimation of interaction. Epidemiology 3:452-456, 1992
29. Sarne DH: A piece of the puzzle: What does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab 97:3094-3096, 2012
30. Xing M: BRAFV600E mutation and papillary thyroid cancer: Chicken or egg? J Clin Endocrinol Metab 97:2295-2298, 2012
31. Puxeddu E, Filetti S: BRAF mutation assessment in papillary thyroid cancer: Are we ready to use it in clinical practice? Endocrine 45:341-343, 2014
32. Elisei R, Viola D, Torregrossa L., et al.: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: Single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390-4398, 2012
33. McLeod DS, Sawka AM, Cooper DS: Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 381:1046-1057, 2013
34. Rivera M, Ricarte-Filho J, Knauf J., et al.: Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23: 1191-1200, 2010
35. Lam AK, Lo CY, Lam KS: Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. Endocr Pathol 16:323-330, 2005
36. Lin HW, Bhattacharyya N: Clinical behavior of follicular variant of papillary thyroid carcinoma: Presentation and survival. Laryngoscope 120:712-716, 2010
37. Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184-199, 2013
38. Zhang Z, Liu D, Murugan A.K., et al.: Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer 21:161-173, 2014